

INCOME STATEMENT
Three months ended 30th September 2007

	Q3 2007 £m	Q3 2006 £m	Growth	
			CER%	£%
Turnover:				
Pharmaceuticals	4,605	4,876	(2)	(6)
Consumer Healthcare	871	766	16	14
TURNOVER	5,476	5,642	1	3
Cost of sales	(1,232)	(1,222)	2	(1)
Gross profit	4,244	4,420	-	(4)
Selling, general and administration	(1,617)	(1,617)	3	-
Research and development	(769)	(871)	(9)	(12)
Other operating income	52	91		
Operating profit:				
Pharmaceuticals	1,707	1,842	(3)	(7)
Consumer Healthcare	203	181	15	12
OPERATING PROFIT	1,910	2,023	(1)	(6)
Finance income	75	64		
Finance expense	(117)	(81)		
Share of after tax profits of associates and joint ventures	14	16		
PROFIT BEFORE TAXATION	1,882	2,022	(2)	(7)
Taxation	(536)	(596)		
<i>Tax rate %</i>	28.5%	29.5%		
PROFIT AFTER TAXATION FOR THE PERIOD	1,346	1,426	(1)	(6)
Profit attributable to minority interests	36	35		
Profit attributable to shareholders	1,310	1,391		
	1,346	1,426		
EARNINGS PER SHARE	23.7p	24.7p	1	(4)
Diluted earnings per share	23.5p	24.4p		

INCOME STATEMENT
Nine months ended 30th September 2007

	9 months 2007 £m	9 months 2006 £m	Growth	
			CER%	£%
Turnover:				
Pharmaceuticals	14,186	14,942	1	(5)
Consumer Healthcare	2,556	2,324	15	10
TURNOVER	16,742	17,266	3	(3)
Cost of sales	(3,678)	(3,565)	6	3
Gross profit	13,064	13,701	2	(5)
Selling, general and administration	(5,131)	(5,323)	2	(4)
Research and development	(2,284)	(2,477)	(4)	(8)
Other operating income	356	207		
Operating profit:				
Pharmaceuticals	5,484	5,624	6	(2)
Consumer Healthcare	521	484	12	8
OPERATING PROFIT	6,005	6,108	6	(2)
Finance income	210	204		
Finance expense	(334)	(266)		
Share of after tax profits of associates and joint ventures	40	43		
PROFIT BEFORE TAXATION	5,921	6,089	5	(3)
Taxation	(1,687)	(1,796)		
Tax rate %	28.5%	29.5%		
PROFIT AFTER TAXATION FOR THE PERIOD	4,234	4,293	7	(1)
Profit attributable to minority interests	77	85		
Profit attributable to shareholders	4,157	4,208		
	4,234	4,293		
EARNINGS PER SHARE	74.7p	74.5p	9	-
Diluted earnings per share	73.9p	73.5p		

PHARMACEUTICAL TURNOVER
Three months ended 30th September 2007

	Total			USA			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
RESPIRATORY	1,185	4	-	570	4	(4)	410	2	3	205	8	6
<i>Seretide/Advair</i>	835	7	3	452	5	(3)	293	8	8	90	15	15
<i>Flixotide/Flovent</i>	140	1	(3)	67	13	5	34	(13)	(13)	39	(5)	(7)
<i>Serevent</i>	63	(6)	(9)	18	(5)	(10)	32	(9)	(9)	13	-	(7)
<i>Flixonase/Flonase</i>	49	(23)	(23)	21	(41)	(46)	10	10	-	18	-	20
CENTRAL NERVOUS SYSTEM	825	(4)	(10)	589	(4)	(11)	124	(13)	(13)	112	5	2
<i>Seroxat/Paxil</i>	128	(2)	(7)	33	9	-	27	(23)	(23)	68	3	(1)
<i>Paxil IR</i>	92	(7)	(11)	-	-	-	27	(23)	(23)	65	3	(2)
<i>Paxil CR</i>	36	12	6	33	13	6	-	-	-	3	-	-
<i>Wellbutrin</i>	135	(38)	(42)	131	(38)	(43)	2	100	100	2	(50)	(50)
<i>Wellbutrin IR, SR</i>	21	(15)	(19)	18	(14)	(18)	1	-	-	2	(33)	(33)
<i>Wellbutrin XL</i>	114	(41)	(45)	113	(41)	(45)	1	-	-	-	-	-
<i>Imigran/Imitrex</i>	165	(2)	(8)	133	-	(8)	22	(19)	(15)	10	10	-
<i>Lamictal</i>	275	14	7	224	20	11	36	(12)	(14)	15	-	7
<i>Requip</i>	87	31	24	59	39	28	23	10	10	5	67	67
ANTI-VIRALS	714	6	2	351	12	4	207	(5)	(5)	156	11	7
HIV	360	3	(1)	159	2	(5)	148	-	(1)	53	17	15
<i>Combivir</i>	115	(4)	(8)	50	(7)	(12)	47	(10)	(10)	18	25	13
<i>Trizivir</i>	55	(8)	(13)	28	(9)	(18)	23	(19)	(15)	4	>100	100
<i>Epivir</i>	38	(13)	(17)	14	(6)	(13)	16	(24)	(24)	8	-	(11)
<i>Ziagen</i>	28	4	-	12	18	9	9	(10)	(10)	7	-	-
<i>Agenerase, Lexiva</i>	37	19	16	20	22	11	13	17	8	4	-	-
<i>Epzicom/Kivexa</i>	80	33	27	34	19	10	37	42	42	9	67	50
Herpes	256	12	6	166	13	4	36	3	-	54	15	17
<i>Valtrex</i>	229	13	7	162	11	3	29	7	4	38	28	31
<i>Zovirax</i>	27	4	-	4	>100	100	7	(13)	(13)	16	(6)	(6)
<i>Zeffix</i>	42	5	-	4	(25)	-	6	-	-	32	9	-
<i>Relenza</i>	28	(7)	(7)	12	>100	>100	14	(44)	(44)	2	-	(67)
METABOLIC	297	(29)	(32)	160	(41)	(45)	65	2	2	72	(13)	(15)
<i>Avandia products</i>	225	(38)	(40)	130	(48)	(51)	50	(11)	(9)	45	(22)	(22)
<i>Avandia</i>	153	(51)	(53)	92	(60)	(62)	26	(17)	(13)	35	(27)	(31)
<i>Avandamet</i>	60	39	36	29	>100	>100	23	(8)	(8)	8	-	33
<i>Avandaryl</i>	12	18	9	9	-	(10)	1	-	-	2	100	100
<i>Bonviva/Boniva</i>	41	56	52	28	24	12	11	>100	>100	2	-	>100
VACCINES	593	49	44	237	97	82	206	22	22	150	35	33
<i>Hepatitis</i>	141	29	24	66	82	69	55	2	2	20	-	(5)
<i>Influenza</i>	141	>100	>100	93	>100	>100	37	>100	>100	11	10	10
<i>Infanrix/Pediarix</i>	137	16	12	58	40	29	62	(5)	(5)	17	33	42
<i>Boostrix</i>	26	56	44	20	50	43	5	67	67	1	100	-
<i>Rotarix</i>	23	>100	>100	-	-	-	6	>100	>100	17	>100	>100
CARDIOVASCULAR AND UROGENITAL	378	(2)	(7)	239	(4)	(11)	96	(1)	-	43	10	5
<i>Coreg</i>	145	(20)	(26)	144	(21)	(25)	-	-	-	1	50	(50)
<i>Coreg CR</i>	31	-	-	31	-	-	-	-	-	-	-	-
<i>Coreg IR</i>	114	(37)	(42)	113	(38)	(41)	-	-	-	1	-	(50)
<i>Levitra</i>	13	18	18	12	33	33	-	-	-	1	(50)	(50)
<i>Avodart</i>	72	33	26	45	27	22	21	29	24	6	>100	100
<i>Arixtra</i>	25	100	92	14	>100	100	9	33	50	2	-	-
<i>Fraxiparine</i>	41	(16)	(16)	-	-	-	35	(20)	(20)	6	20	20
<i>Vesicare</i>	13	56	44	13	56	44	-	-	-	-	-	-
ANTI-BACTERIALS	302	(2)	(3)	41	(15)	(21)	130	(4)	(4)	131	6	6
<i>Augmentin</i>	117	(2)	(3)	11	(40)	(45)	54	-	-	52	11	11
ONCOLOGY AND EMESIS	104	(61)	(63)	52	(74)	(77)	35	(8)	(5)	17	(5)	(11)
<i>Zofran</i>	32	(86)	(86)	4	(98)	(98)	17	(32)	(32)	11	(8)	(15)
<i>Hycamtin</i>	30	11	7	18	12	6	11	10	10	1	-	-
<i>Tykerb</i>	16	-	-	11	-	-	5	-	-	-	-	-
OTHER	207	(9)	(10)	(9)	-	-	63	2	3	153	5	2
<i>Zantac</i>	37	(25)	(27)	5	(69)	(69)	10	(9)	(9)	22	(4)	(8)
	4,605	(2)	(6)	2,230	(7)	(13)	1,336	1	1	1,039	9	6

Pharmaceutical turnover includes co-promotion income.

PHARMACEUTICAL TURNOVER
Nine months ended 30th September 2007

	Total			USA			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
RESPIRATORY	3,669	4	(2)	1,745	3	(5)	1,294	3	2	630	9	2
<i>Seretide/Advair</i>	2,541	10	4	1,378	9	-	900	8	7	263	18	12
<i>Flixotide/Flovent</i>	446	(2)	(8)	203	1	(7)	117	(10)	(11)	126	(1)	(8)
<i>Serevent</i>	198	(4)	(9)	55	(6)	(14)	99	(7)	(7)	44	4	(4)
<i>Flixonase/Flonase</i>	167	(34)	(37)	71	(56)	(57)	39	-	(3)	57	7	2
CENTRAL NERVOUS SYSTEM	2,449	(3)	(10)	1,740	(1)	(10)	380	(16)	(17)	329	4	(4)
<i>Seroxat/Paxil</i>	402	(5)	(12)	104	(10)	(17)	93	(18)	(18)	205	4	(6)
<i>Paxil IR</i>	288	(8)	(14)	2	(81)	(88)	93	(18)	(18)	193	3	(6)
<i>Paxil CR</i>	114	2	(7)	102	1	(7)	-	-	-	12	8	-
<i>Wellbutrin</i>	399	(37)	(42)	387	(38)	(43)	3	50	50	9	(25)	(25)
<i>Wellbutrin IR, SR</i>	59	(19)	(23)	50	(21)	(25)	2	-	-	7	(13)	(13)
<i>Wellbutrin XL</i>	340	(39)	(44)	337	(39)	(44)	1	-	-	2	(50)	(50)
<i>Imigran/Imitrex</i>	498	-	(7)	405	7	(2)	65	(30)	(30)	28	-	(10)
<i>Lamictal</i>	796	16	8	645	26	15	107	(20)	(21)	44	10	5
<i>Requip</i>	251	40	31	174	53	40	66	10	10	11	63	38
ANTI-VIRALS	2,237	12	5	1,102	18	8	663	4	3	472	12	4
HIV	1,083	(1)	(6)	482	(1)	(9)	456	(3)	(4)	145	5	(2)
<i>Combivir</i>	347	(10)	(15)	150	(10)	(18)	147	(12)	(13)	50	(5)	(14)
<i>Trizivir</i>	177	(9)	(14)	92	(7)	(16)	74	(15)	(16)	11	20	10
<i>Epivir</i>	119	(21)	(25)	40	(19)	(26)	52	(26)	(28)	27	(12)	(18)
<i>Ziagen</i>	81	(3)	(9)	34	3	(6)	28	(10)	(10)	19	(5)	(14)
<i>Agenerase, Lexiva</i>	105	14	8	59	18	7	39	11	8	7	-	17
<i>Epzicom/Kivexa</i>	234	44	36	105	25	14	106	57	56	23	>100	92
Herpes	758	13	5	494	19	8	110	4	2	154	4	(3)
<i>Valtrex</i>	679	16	7	487	18	8	87	9	6	105	11	4
<i>Zovirax</i>	79	(7)	(12)	7	33	17	23	(12)	(12)	49	(9)	(16)
<i>Zeffix</i>	126	12	5	10	-	-	18	6	6	98	14	5
<i>Relenza</i>	187	>100	>100	90	>100	>100	72	83	80	25	86	79
METABOLIC	1,193	(9)	(15)	729	(17)	(24)	215	19	17	249	1	(5)
<i>Avandia products</i>	988	(14)	(20)	650	(21)	(28)	170	7	6	168	-	(5)
<i>Avandia</i>	717	(28)	(33)	493	(34)	(40)	88	(7)	(7)	136	(8)	(14)
<i>Avandamet</i>	228	77	68	121	>100	>100	80	25	23	27	59	59
<i>Avandaryl</i>	43	68	54	36	54	38	2	-	-	5	>100	>100
<i>Bonviva/Boniva</i>	109	90	79	77	55	40	30	>100	>100	2	100	>100
VACCINES	1,359	21	17	424	52	34	556	10	9	379	11	7
<i>Hepatitis</i>	382	14	9	145	35	23	170	3	2	67	6	2
<i>Influenza</i>	146	>100	>100	93	>100	>100	37	>100	>100	16	(11)	(11)
<i>Infanrix/Pediarix</i>	406	13	8	152	34	22	201	(3)	(4)	53	32	29
<i>Boostrix</i>	53	33	26	34	32	21	14	40	40	5	25	25
<i>Rotarix</i>	52	>100	>100	-	-	-	16	>100	>100	36	100	89
CARDIOVASCULAR AND UROGENITAL	1,256	11	3	834	15	5	299	3	2	123	1	(5)
<i>Coreg</i>	564	6	(3)	558	6	(3)	-	-	-	6	40	20
<i>Coreg CR</i>	55	-	-	54	-	-	-	-	-	1	-	-
<i>Coreg IR</i>	509	(4)	(12)	504	(4)	(12)	-	-	-	5	20	-
<i>Levitra</i>	38	32	23	36	34	33	-	-	-	2	100	100
<i>Avodart</i>	202	39	30	126	44	33	60	22	20	16	80	60
<i>Arixtra</i>	71	>100	92	39	>100	95	28	75	75	4	>100	>100
<i>Fraxiparine</i>	133	(13)	(15)	-	-	-	117	(13)	(13)	16	(19)	(24)
<i>Vesicare</i>	36	70	57	36	70	57	-	-	-	-	-	-
ANTI-BACTERIALS	960	(2)	(5)	143	(3)	(11)	436	(5)	(6)	381	2	(3)
<i>Augmentin</i>	384	(7)	(10)	52	(19)	(25)	179	(10)	(11)	153	3	(1)
ONCOLOGY AND EMESIS	377	(54)	(56)	227	(64)	(66)	101	(15)	(16)	49	(16)	(21)
<i>Zofran</i>	174	(74)	(74)	85	(84)	(85)	54	(36)	(37)	35	(21)	(26)
<i>Hycamtin</i>	88	9	4	53	7	(2)	30	19	15	5	(20)	-
<i>Tykerb</i>	32	-	-	24	-	-	8	-	-	-	-	-
OTHER	686	-	(4)	32	(48)	(51)	186	2	2	468	6	-
<i>Zantac</i>	125	(25)	(29)	26	(50)	(54)	31	(18)	(21)	68	(11)	(17)
	14,186	1	(5)	6,976	(2)	(10)	4,130	1	-	3,080	6	1

Pharmaceutical turnover includes co-promotion income.

CONSUMER HEALTHCARE TURNOVER
Three months ended 30th September 2007

	Q3 2007 £m	Growth	
		CER%	£%
Over-the-counter medicines	417	24	20
Analgesics	104	16	14
Dermatological	43	16	16
Gastrointestinal	62	8	2
Respiratory tract	61	63	61
Smoking control	75	8	3
Natural wellness support	31	(9)	(9)
Weight management	34	-	-
Oral care	260	11	8
Nutritional healthcare	194	8	9
Total	871	16	14

CONSUMER HEALTHCARE TURNOVER
Nine months ended 30th September 2007

	9 months 2007 £m	Growth	
		CER%	£%
Over-the-counter medicines	1,238	20	14
Analgesics	304	11	7
Dermatological	127	8	4
Gastrointestinal	194	10	3
Respiratory tract	161	47	41
Smoking control	228	(3)	(9)
Natural wellness support	90	(5)	(8)
Weight management	110	-	-
Oral care	774	10	5
Nutritional healthcare	544	10	8
Total	2,556	15	10